Report Overview

United States Human Insulin Market is growing rapidly due to the growing elderly population, an increasing number of diabetic patients, growing prevalence of obesity, and an increasing demand for better and more efficient treatments.

United States Human Insulin Market - Industry Trends & Forecast Report 2028

United States Human Insulin market is expected to grow at a CAGR of 4.1% during the forecast period (2022-2028). Market growth is driven by an increasing elderly population, an increasing number of diabetic patients, a growing prevalence of obesity, and an increasing demand for better and more efficient treatments. A huge number of younger generations are diagnosed with diabetes and irregular blood sugar levels. This increase in the number of young diabetics is expected to drive market growth over the forecast period. Technological advances in gadgets that make life easier and more comfortable have forced young people into obesity, a lazy lifestyle, and many health problems that disrupt blood sugar levels in the body, indirectly influencing the growth of the United States human insulin market. Strict regulatory requirements for cost efficiency, reimbursement pricing, and insulin approval are expected to support the growth of the insulin market for humans in the United States.

Human Insulin – Overview

Human insulin refers to synthetic insulin grown in the laboratory to mimic human insulin. In the lab, human insulin was made from Escherichia coli insulin protein within E-coli bacteria (Escherichia Coli). They come in two forms, a short-acting regular form and Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, which is a cloudy suspension. Insulin acts as a hormone that regulates the body's blood sugar levels. Diabetes is a chronic disease in which a person's blood sugar levels are high. Currently, there are two main types of diabetes. Type 1 diabetes is a condition in which pancreatic beta cells stop producing insulin, and type 2 diabetes is a condition in which pancreatic cells cannot produce insulin.

United States Human Insulin Market Forecast and Trends

Growth Drivers

New Research and Development Activities to drive the Market Growth

Several organizations boost the United States human insulin market by increased investment in research and development activities. That led to advanced and easy methods of injecting insulin. For example, Fiasp (Novo Nordisk) is a formulation of insulin aspart in combination with niacinamide (vitamin B3) that may improve the initial absorption of the drug. Afrezza (Mannkind) is the only inhalation form on the market that eliminates the need for needles and syringes. In addition, key players are developing pen devices and safety pen needles to provide Human Insulin in the body, reducing discomfort and reducing the risk of injury, infection, and transmission of pathogens through the blood. Significant improvements in the healthcare infrastructure and extensive R & D in biotechnology activities by leading players in the industry ensure a positive market outlook.

The growing prevalence of Diabetic patients to boost the market growth

According to a Diabetes Statistics Report released by the Centers for Disease Control and Prevention (CDC), the United States has a Diabetes patient population of approximately 37.3 million people have diabetes (11.3% of the U.S. population). One main factor that positively impacts the global demand for human insulin (H.I.) is the increased prevalence of diabetes resulting from sedentary lifestyles, unhealthy diets, and high-stress levels. The growing elderly population susceptible to diabetes also drives the market's growth.

Restraints

The highly concentrated market and increasing cost of insulin

The high cost of insulin may hinder market growth. Leading three companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, have patent protection for their products. For example, Sanofi has applied for Admelog 74 patents to strengthen its position. These companies account for more than 90% of the global market. As a result, there are only a few biosimilar players in this market.

Impact of COVID-19 on the United States Human Insulin Market

The Covid-19 outbreak has certainly turned the healthcare industry upside down. This is due to the significant disruptions experienced in manufacturing and supply chain operations as a result of various preventive lockdowns and other restrictions implemented by government agencies around the world. The same applies to the US market for human insulin. Moreover, with most individuals' overall economic situation severely impacted by this outbreak, consumer demand is also declining as individuals become keen to cut unnecessary expenses from their respective budgets. In addition, hospitals have reported a decrease in insulin prescriptions. These above-mentioned factors are expected to affect the revenue growth of the United States human insulin market during the forecast period. However, the impact of COVID-19 has eased since the second quarter of 2021 and helped the US human insulin market regain momentum.

United States Human Insulin Market - By Type

Based on type human insulin market is segmented into insulin analogs and biosimilars, and human insulin biologics. Insulin analogs and biosimilars were further bifurcated into long-acting biosimilars, rapid-acting biosimilars, and premixed biosimilars. Human insulin biologics are further segmented into short-acting biologics, intermediate-acting biologics, and premixed biologics. The insulin analogs and biosimilars segment dominated the market in 2021. Its superiority is due to higher insulin potency and minimal side effects such as fewer hypoglycemic episodes and less weight gain compared to conventional therapy.

Among all insulin analogs and biosimilars, the long-acting insulin category held the largest share in the market in 2021. Long-acting insulin analogs such as glargine, detemir, and degludec are being developed by Eli Lilly, Novo Nordisk A/S, and Sanofi, respectively. These products have a high market share, and their demand is expected to drive the market. 

United States Human Insulin Market - By Distribution Channel

Based on distribution channels, the United States human insulin market is segmented into three types: retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacy segment dominated the overall market in 2021 owing to the increasing burden of illness, the potential for patients' home care, and various discount offers from retail pharmacies. The market is consolidated with retail pharmacy chains across the United States. In addition, modest growth is expected in the hospital pharmacy segment. This segment is driven by factors such as increasing hospitalizations for diabetics.

Online pharmacies are expected to register the fastest growth during the forecast period. The convenience and flexibility of patients by purchasing medicines online are key factors driving this segment. Additionally, the discounts offered by online pharmacies entice patients to purchase their medications online. This is also expected to drive market growth.

Competitive Landscape

The United States Human Insulin market is highly concentrated due to the presence of only three key players, Novo Nordisk, Sanofi, and Eli Lilly. These three companies are commonly referred to as the "Big 3" because they dominate more than 90% of the global insulin market. The key Players operating in the United States human insulin market are AstraZeneca PLC, Biocon Limited, Dongbao Enterprise Group Co., Ltd., Eli Lilly and Company, GmbH, Julphar, Novartis International AG, Novo Nordisk A/S, Pfizer Inc., Sanofi SA, Tonghua Dongbao Pharmaceutical Co., Ltd, and Wockhardt Ltd. Market leaders maintain their growth advantage by investing in research and development, incorporating cutting-edge technology into their products, and releasing improved items to their customers. Various tactics are used, including strategic alliances, agreements, mergers, and partnerships.

Recent Developments

• August 2021 – The U.S. Food and Drug Administration (FDA) has announced that Eli Lilly and Company's fast-acting insulin Lyumjev (Insulin Lispro-AABC Injection), 100 units / mL, is used to improve glycemic control in type 1 and type 2 adults, approved expansion label for administration by continuous subcutaneous insulin infusion (CSII) using an insulin pump.

• July 2021 - Semglee is the first insulin product of its kind. Manufactured by Biocon Biologics, a Bengaluru-based pharmaceutical company, and approved in the U.S., Semglee is compatible and biosimilar to Lantus, a long-acting insulin product already approved in the United States.

Scope of the Report

By Product Type

• Human Insulin Drugs

• Human Insulin Delivery Devices

By Type

• Insulin Analogs and Biosimilars

  • Long-Acting Biosimilars

  • Rapid-Acting Biosimilars

  • Premixed Biosimilars

• Human Insulin Biologics

  • Short-Acting Biologics

  • Intermediate-Acting Biologics

  • Premixed Biologics

By Delivery Devices

• Syringes

• Pens

  • Disposable Pens

  • Reusable Pens

• Pen Needles

  • Standard Pen Needles

  • Safety Pen Needles

By Application

• Type I Diabetes

• Type II Diabetes

By Distribution Channel

• Retail Pharmacies

• Hospital Pharmacies

• Online Pharmacies